I would have rather seen the share price go up today rather than down, but maybe that's just me. Saying whether or not we hit the primary endpoint, how many deaths occurred in each arm, and what the p-value was, if these things are good news, would have caused an up- rather than a down - tick in the share price today. That in turn would have led to a higher value for leronlimab for treating severe to critical COVID patients if in fact any negotiations are ongoing with private industry or the government.

From the pr - "Details of the Company’s ongoing discussions with the regulatory agencies are confidential." OK, perhaps management has been advised not to say anything about the results of the trial. I'm cool with that, I guess. But if that's the case, I'd like to see Uncle Sam come through with some huge funding.

5th and final post for today